Medical Mythbusting Commentary for June 1, 2026

Source:
‘I actually started crying’: Oncologist reacts to pancreatic cancer drug results

Synopsis of the article and study:

• Researchers developed daraxonrasib, an experimental oral pill.
• It targets mutated RAS protein driving over 90% of pancreatic cancers.
• In Phase 3 RASolute 302 trial for previously treated metastatic pancreatic cancer, patients received daraxonrasib or standard chemotherapy.
• Daraxonrasib nearly doubled median overall survival to 13.2 months vs. 6.7 months with chemo.
• It improved progression-free survival to 7.3 months.
• The drug showed better tolerability with fewer treatment discontinuations.
• Presented at ASCO meeting in 2026; FDA expanded access available, approval pending.

Benefits: Doubled survival, oral convenience, targeted action, manageable side effects.

Limitations: Grade 3+ adverse events in about one-third of patients; still experimental, not yet fully approved; tested in advanced cases post-chemo.